Prevalence of TP53 Gene Mutation in GBM Patients in Egyptian Population | ||||
| The Medical Journal of Cairo University | ||||
| Volume 92, Issue 09, September 2024, Page 809-814 PDF (110.26 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2024.390032 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| AHMED H. ABDELSATTAR, M.Sc.; MOHAMED R. ABDELGHANY, M.D.; MOHAMED Sh.S. ZAGLOUL, M.D. and MOHAMED A. GOUDA, M.D. | ||||
| The Department of Neurosurgery, Faculty of Medicine, Cairo University | ||||
| Abstract | ||||
| Abstract Background: Glioblastoma Multiforme (GBM) is one of the most fatal of all brain tumors. TP53 mutation is the hall-mark genetic mutation of GBM, because these tumors have a high incidence of mutation in this gene (>65%), suggesting that p53 pathway has an important role in the development of the tumors. Aim of Study: This study aimed to assess the prevalence of TP53 gene mutation in Glioblastoma multiforme patients and its correlation to the clinical pictures of this tumors in Egypt. Patients and Methods: This retrospective cross-sectional study included 59 patients pathologically confirmed of having GBM after surgical excision, underwent further immunological analysis of presence of TP53 gene mutation. Results: Patients with TP53 presented with DCL (p-value =0.703), fits (p-value=0.677), weakness (p-value=0.212) were statistically insignificant. Conclusion: Patients diagnosed with TP53 gene mutation didn’t present with significantly different clinical picture from other patients. | ||||
| Keywords | ||||
| Glioblastoma Multiforme; TP53; Gene Mutation and Astrocytomas | ||||
|
Statistics Article View: 118 PDF Download: 65 |
||||
